Connective tissue growth factor and β -catenin constitute an autocrine loop for activation in rat sarcomatoid mesothelioma

Journal of Pathology

Volumn 233, Issue 4, 2014, Pages 402-414

  Jiang, Li ^a   Yamashita, Yoriko ^a   Chew, Shan Hwu ^a   Akatsuka, Shinya ^a   Ukai, Shun ^a   Wang, Shenqi ^a   Nagai, Hirotaka ^a   Okazaki, Yasumasa ^a   Takahashi, Takashi ^a   Toyokuni, Shinya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

connective tissue growth factor; mesothelioma; sarcomatoid mesothelioma; serum marker; catenin

Indexed keywords

ASBESTOS; BETA CATENIN; CONNECTIVE TISSUE GROWTH FACTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; MALE; MALIGNANT MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

CONNECTIVE TISSUE GROWTH FACTOR; MESOTHELIOMA; SARCOMATOID MESOTHELIOMA; SERUM MARKER; Β-CATENIN;

ANIMALS; AUTOCRINE COMMUNICATION; BETA CATENIN; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; EPITHELIUM; FEMALE; GLYCOGEN SYNTHASE KINASE 3; LUNG NEOPLASMS; MALE; MESOTHELIOMA; RATS; RATS, INBRED F344; SARCOMA; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904250717     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4377     Document Type: Article

References (42)

1. Roggli VL, Oury TD, Sporn TA,. Pathology of Asbestos-associated Diseases, 2nd edn. Springer: New York, 2004.
2. Huang SX, Jaurand MC, Kamp DW, et al., Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev 2011; 14: 179-245.
3. World Health Organization (WHO). Asbestos (chrysotile, amosite, crocidolite, tremolite, actinolite and anthophyllite). In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: A Review of Human Carcinogens; Part C: Arsenic, Metals, Fibres and Dusts. IARC: Lyon, France, 2012; 219-309.
4. Robinson B, Lake R,. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.
5. Hodgson JT, McElvenny DM, Darnton AJ, et al., The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587-593.
6. Delgermaa V, Takahashi K, Park EK, et al., Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Org 2011; 89: 716-724, 724A-C.
7. van der Bij S, Koffijberg H, Burgers JA, et al., Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 2012; 107: 161-164.
8. Rusch V, Baldini EH, Bueno R, et al., The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, MA. J Thorac Cardiovasc Surg 2013; 145: 909-910.
9. Bolukbas S, Manegold C, Eberlein M, et al., Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011; 71: 75-81.
10. Churg A, Cagle PT, Roggli VL,. Tumors of the Serosal Membranes. ARP Press: Silver Spring, MD, 2006.
11. Attanoos RL, Dojcinov SD, Webb R, et al., Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000; 37: 224-231.
12. Husain AN, Colby TV, Ordonez NG, et al., Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133: 1317-1331.
13. Jiang L, Akatsuka S, Nagai H, et al., Iron overload signature in chrysotile-induced malignant mesothelioma. J Pathol 2012; 228: 366-377.
14. Usami N, Fukui T, Kondo M, et al., Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 387-394.
15. Hu Q, Akatsuka S, Yamashita Y, et al., Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 2010; 90: 360-373.
16. Nagai H, Okazaki Y, Chew S, et al., Diameter of multi-walled carbon nanotubes is a critical factor in mesothelial injury and subsequent carcinogenesis. Proc Natl Acad Sci USA 2011; 108: E1330-1338.
17. Okazaki Y, Nagai H, Chew SH, et al., CD146 and insulin-like growth factor 2 mRNA-binding protein 3 predict prognosis of asbestos-induced rat mesothelioma. Cancer Sci 2013; 104: 989-995.
18. Toyokuni S, Kawaguchi W, Akatsuka S, et al., Intermittent microwave irradiation facilitates antigen-antibody reaction in western blot analysis. Pathol Int 2003; 53: 259-261.
19. Tanaka T, Akatsuka S, Ozeki M, et al., Redox regulation of annexin 2 and its implications for oxidative stess-induced renal carcinogenesis and metastasis. Oncogene 2004; 23: 3980-3989.
20. Arnott JA, Lambi AG, Mundy C, et al., The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Crit Rev Eukaryot Gene Expr 2011; 21: 43-69.
21. Zhou T, Zhou KK, Lee K, et al., The role of lipid peroxidation products and oxidative stress in activation of the canonical wingless-type MMTV integration site (WNT) pathway in a rat model of diabetic retinopathy. Diabetologia 2011; 54: 459-468.
22. Dajani R, Fraser E, Roe SM, et al., Structural basis for recruitment of glycogen synthase kinase 3β to the axin-APC scaffold complex. EMBO J 2003; 22: 494-501.
23. Clevers H., Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-480.
24. Ishitani T, Ninomiya-Tsuji J, Nagai S, et al., The TAK1-NLK-MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF. Nature 1999; 399: 798-802.
25. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
26. Fujii M, Toyoda T, Nakanishi H, et al., TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med 2012; 209: 479-494.
27. Perbal B., CCN proteins: a centralized communication network. J Cell Commun Signal 2013; 7: 169-177.
28. Perbal B., CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-64.
29. Mercurio S, Latinkic B, Itasaki N, et al., Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development 2004; 131: 2137-2147.
30. Ren S, Johnson BG, Kida Y, et al., LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA 2013; 110: 1440-1445.
31. Gao R, Brigstock DR,. Low density lipoprotein receptor-related protein (LRP) is a heparin-dependent adhesion receptor for connective tissue growth factor (CTGF) in rat activated hepatic stellate cells. Hepatol Res 2003; 27: 214-220.
32. Ball DK, Rachfal AW, Kemper SA, et al., The heparin-binding 10 kDa fragment of connective tissue growth factor (CTGF) containing module 4 alone stimulates cell adhesion. J Endocrinol 2003; 176: R1-7.
33. Lau LF, Lam SC,. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999; 248: 44-57.
34. Jacobson A, Cunningham JL,. Connective tissue growth factor in tumor pathogenesis. Fibrogen Tissue Repair 2012; 5 (suppl 1): S8.
35. Uematsu K, Kanazawa S, You L, et al., Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of β-catenin. Cancer Res 2003; 63: 4547-4551.
36. You L, He B, Uematsu K, et al., Inhibition of Wnt-1 signaling induces apoptosis in β-catenin-deficient mesothelioma cells. Cancer Res 2004; 64: 3474-3478.
37. Harvey KF, Zhang X, Thomas DM,. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246-257.
38. Sekido Y., Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol Int 2011; 61: 331-344.
39. Deng YZ, Chen PP, Wang Y, et al., Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through β-catenin-T cell factor-Lef signaling. J Biol Chem 2007; 282: 36571-36581.
40. Hassan R, Ho M,. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44: 46-53.
41. Robinson BW, Musk AW, Lake RA,. Malignant mesothelioma. Lancet 2005; 366: 397-408.
42. Finger EC, Cheng CF, Williams TR, et al., CTGF is a therapeutic target for metastatic melanoma. Oncogene 2014; 33: 1093-1100.